Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: microRNA therapeutics - Viridian Therapeutics

Drug Profile

Research programme: microRNA therapeutics - Viridian Therapeutics

Alternative Names: AntimiR-15; AntimiR-155; AntimiR-208; AntimiRNA-15; LNA antimiR; MGN 7455; MGN-4893; mimics of the microRNA-183/96/182 - Viridian Therapeutics; miR-143/145; miR-15/195; miR-206; miR-208; miR-208/499; miR-29; miR-499; miR-92/126; miR-92a; MIRG-9103; miRNA-145 inhibitor; MRG-107

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Servier; University of Glasgow; University of Texas Southwestern Medical Center; Viridian Therapeutics
  • Class Cardiovascular therapies; Eye disorder therapies; MicroRNAs; Neuroprotectants
  • Mechanism of Action MicroRNA inhibitors; MIRN145-microRNA-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Cardiovascular disorders; Heart failure; Hypertrophic cardiomyopathy; Ischaemia; Postmyocardial infarction; Retinal disorders
  • Discontinued Coronary artery restenosis; Fibrosis; Polycythaemia vera; Pulmonary arterial hypertension

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Parenteral)
  • 19 Jan 2021 miRagen Therapeutics is now called Viridian Therapeutics
  • 28 Jul 2020 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top